These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach RS, Mukherjee R, Iannini JP, O SJ. Circulation; 1997 Oct 07; 96(7):2385-96. PubMed ID: 9337215 [Abstract] [Full Text] [Related]
15. Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. Azizi M, Blanchard A, Charbit B, Wuerzner G, Peyrard S, Ezan E, Funck-Brentano C, Ménard J. Hypertension; 2013 Jun 07; 61(6):1239-45. PubMed ID: 23608658 [Abstract] [Full Text] [Related]
16. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. Boutouyrie P, Beaussier H, Achouba A, Laurent S, EXPLOR trialists. J Hypertens; 2014 Jan 07; 32(1):108-14. PubMed ID: 24275838 [Abstract] [Full Text] [Related]
17. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. Daneshtalab N, Lewanczuk RZ, Russell A, Jamali F. J Clin Pharmacol; 2004 Mar 07; 44(3):245-52. PubMed ID: 14973301 [Abstract] [Full Text] [Related]
18. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A. Clin Ther; 2009 Sep 07; 31(9):1992-2001. PubMed ID: 19843489 [Abstract] [Full Text] [Related]